Abstract: Methods of diagnosing graft versus host disease (GVHD) comprising quantifying cfDNA or employing a machine learning model are provided. Methods comprising training a machine learning model are also provided.

Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.

Abstract: The present disclosure relates generally to compositions and methods for determining cell type based on a methylation profile of associated DNA. For cell free DNA, such determination can be used to identify disease or conditions relating to the cell type. For tumor cells, such determination is useful for identifying their primary origin.

Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.

Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.

Abstract: Primer sets comprising a 3? region of homology to a 5? segment of a target nucleic acid molecule and a 5? first adapter sequence wherein the first adapter sequence comprises a 5? first and 3? second region and wherein said first region is between 50% and 99% of the first adapter sequence; and a second primer comprising a 3? region identical to the first region of the first adapter sequence and a 5? second adapter sequence are provided. Methods of performing polymerase chain reaction (PCR), producing a sequencing library and determining the cell type of origin of cell free DNA (cfDNA) are also provided.

Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.

Abstract: Methods of detecting DNA from a cancerous cell comprising receiving measurements of DNA methylation in at least one genomic region are provided. Arrays comprising at least 10 methylation specific oligonucleotides, wherein the methylation specific oligonucleotides are each reverse complementary to a genomic region are also provided.

Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.

Abstract: Methods of determining the origin of cell free DNA (cfDNA) and for detecting death of a cell type or tissue in a subject by determining the origin of cfDNA in the subject are provided. Computer program products, computerized methods and computerized systems for doing same, as well as methods for constructing a methylome atlas, are also provided.

Abstract: A method of ascertaining the methylation status of a double-stranded, cell-free DNA molecule in a specimen is disclosed. The method comprises ascertaining the methylation status of at least two methylation sites of the same double-stranded cell-free DNA molecule, wherein said double-stranded, cell-free DNA molecule comprises a nucleotide sequence which comprises no more than 300 base pairs and is comprised in a sequence as set forth in any one of SEQ ID NOs: 2-117 or 121-177.

Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.

Abstract: A method of determining the methylation status of at least one methylation site of a double-stranded DNA molecule is disclosed. The method comprises analyzing the methylation status of both the forward strand and the reverse strand of the DNA molecule.

Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.

Abstract: The present invention relates to in vivo and in vitro methods for controlling proliferation of glucose regulated insulin-producing beta cells by modulating the expression or the activity of the cyclin-dependent kinase inhibitor p57Kip2. The invention further provides recombinant glucose regulated insulin-producing beta cell or cell-line having controlled proliferation and compositions and uses thereof in methods for treatment of diabetes type I, diabetes type II and hyperinsulinism of infancy.